131 related articles for article (PubMed ID: 30084943)
1. Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus-Infected Individuals.
Cerrone M; Wang X; Neary M; Weaver C; Fedele S; Day-Weber I; Owen A; Hill A; McClure M; Boffito M
Clin Infect Dis; 2019 Jan; 68(3):446-452. PubMed ID: 30084943
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum.
Lamorde M; Wang X; Neary M; Bisdomini E; Nakalema S; Byakika-Kibwika P; Mukonzo JK; Khan W; Owen A; McClure M; Boffito M
Clin Infect Dis; 2018 Aug; 67(5):785-790. PubMed ID: 30124823
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R;
Clin Pharmacol Ther; 2015 Oct; 98(4):406-16. PubMed ID: 26044067
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study.
Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R
Clin Pharmacokinet; 2016 Jul; 55(7):861-873. PubMed ID: 26715213
[TBL] [Abstract][Full Text] [Related]
6. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin.
Wang X; Cerrone M; Ferretti F; Castrillo N; Maartens G; McClure M; Boffito M
Int J Antimicrob Agents; 2019 Aug; 54(2):202-206. PubMed ID: 31002950
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of efavirenz in HIV and TB/HIV coinfected children: the significance of genotype-guided dosing.
Alghamdi WA; Antwi S; Enimil A; Yang H; Dompreh A; Wiesner L; Langaee T; Peloquin CA; Kwara A
J Antimicrob Chemother; 2019 Sep; 74(9):2698-2706. PubMed ID: 31243456
[TBL] [Abstract][Full Text] [Related]
9. Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Podany AT; Bao Y; Swindells S; Chaisson RE; Andersen JW; Mwelase T; Supparatpinyo K; Mohapi L; Gupta A; Benson CA; Kim P; Fletcher CV;
Clin Infect Dis; 2015 Oct; 61(8):1322-7. PubMed ID: 26082504
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.
Atwine D; Bonnet M; Taburet AM
Br J Clin Pharmacol; 2018 Aug; 84(8):1641-1658. PubMed ID: 29624706
[TBL] [Abstract][Full Text] [Related]
12. The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.
Bienvenu E; Swart M; Dandara C; Ashton M
Antiviral Res; 2014 Feb; 102():44-53. PubMed ID: 24316028
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens.
Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK
HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898
[TBL] [Abstract][Full Text] [Related]
14. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?
Orrell C; Cohen K; Conradie F; Zeinecker J; Ive P; Sanne I; Wood R
Antivir Ther; 2011; 16(4):527-34. PubMed ID: 21685540
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of Efavirenz 600 mg Once Daily During Pregnancy and Post Partum in Ghanaian Women Living With HIV.
Lartey M; Kenu E; Lassey A; Ntumy M; Ganu V; Sam M; Boamah I; Gilani FS; Yang H; Burch GM; Norman J; Peloquin CA; Kwara A
Clin Ther; 2020 Sep; 42(9):1818-1825. PubMed ID: 32811669
[TBL] [Abstract][Full Text] [Related]
16. CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.
Mukonzo JK; Bisaso RK; Ogwal-Okeng J; Gustafsson LL; Owen JS; Aklillu E
Pharmacogenomics; 2016 Apr; 17(6):603-13. PubMed ID: 27045425
[TBL] [Abstract][Full Text] [Related]
17. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
Luetkemeyer AF; Rosenkranz SL; Lu D; Marzan F; Ive P; Hogg E; Swindells S; Benson CA; Grinsztejn B; Sanne IM; Havlir DV; Aweeka F;
Clin Infect Dis; 2013 Aug; 57(4):586-93. PubMed ID: 23592830
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
Swaminathan S; Padmapriyadarsini C; Venkatesan P; Narendran G; Ramesh Kumar S; Iliayas S; Menon PA; Selvaraju S; Pooranagangadevi NP; Bhavani PK; Ponnuraja C; Dilip M; Ramachandran R
Clin Infect Dis; 2011 Oct; 53(7):716-24. PubMed ID: 21890776
[TBL] [Abstract][Full Text] [Related]
19. Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.
Kwara A; Yang H; Antwi S; Enimil A; Gillani FS; Dompreh A; Ortsin A; Opoku T; Bosomtwe D; Sarfo A; Wiesner L; Norman J; Alghamdi WA; Langaee T; Peloquin CA; Court MH; Greenblatt DJ
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397066
[TBL] [Abstract][Full Text] [Related]
20. Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
Chirehwa MT; McIlleron H; Wiesner L; Affolabi D; Bah-Sow O; Merle C; Denti P;
J Antimicrob Chemother; 2019 Jan; 74(1):139-148. PubMed ID: 30239829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
